gta gene and toms automotive LLC

6412 south transit rd.
bay 2
lockport, new york 14094

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 05, 2014

NYS DOS ID#
4617162

County
NIAGARA

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - GTA GENE AND TOMS AUTOMOTIVE LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Tom Colicchio Changes His Restaurant’s Racially Tinged Name
    By KIM SEVERSON - Wednesday Aug 23, 2017

    The chef is renaming Fowler & Wells, after learning about the name’s connection with the debunked theories of phrenology.

    Source: NYT > Home Page
  • Single-player modding returns to GTA V after publisher takedown
    By Kyle Orland - Saturday Jun 24, 2017

    Popular OpenIV tool restored after discussions, changes to protect multiplayer.

    Source: Ars Technica
  • ‘GTA Online’ Hackers Might’ve Just Spoiled A Major Event Early
    By Dan MacRae - Saturday Jul 1, 2017

    A dogged band of 'Grand Theft Auto' explorers have uncovered something big.

    Source: Uproxx
  • Spotify’s head of video and podcasts departs amid strategy shift
    By Katie Roof - Friday Sep 1, 2017

     Tom Calderone, Spotify’s head of video and podcasts, is departing the company amid a shift in content strategy.  The news was first identified by Bloomberg.  The digital streaming business, known for its music playlists, had expanded into other categories like original video, but the company has confirmed that it’s changing its approach. Said a spokesperson, going forward… Read More

    Source: TechCrunch
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy VC, Deals, & Startups Feed